Physician profile
Richard S Crawford
NPI 1164528261
$126,020.52
in general payments reported to CMS, 2019-2025
23 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $22K · 2021: $16K · 2022: $20K · 2023: $5,962 · 2024: $4,908 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $1,637 · Travel and Lodging: $1,416 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,494.50 |
| Food and Beverage | $1,637.37 |
| Travel and Lodging | $1,416.47 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $74,224.66 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,634.04 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $11,824.80 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $9,864.63 | 2020 | |
| Lilly USA, LLC | $9,747.14 | 2019-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $4,654.11 | 2020-2025 | |
| Medtronic, INC. | $217.36 | 2024-2025 | Minimed 780g |
| Amgen INC. | $162.60 | 2023-2025 | Evenity, Prolia, Tepezza |
| Pfizer INC. | $129.07 | 2022-2025 | |
| Horizon Therapeutics Plc | $124.13 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $73.89 | 2025 | |
| Ascendis Pharma Endocrinology INC | $46.71 | 2025 | Yorvipath |
| Chiesi USA, INC. | $42.71 | 2024-2025 | Mycapssa |
| Dexcom, INC. | $37.53 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $37.16 | 2024-2025 | Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.98 | 2025 | |
| Tandem Diabetes Care, INC. | $31.50 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $27.13 | 2024-2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $26.76 | 2025 | Teriparatide |
| Xeris Pharmaceuticals, INC. | $24.89 | 2025 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $20.19 | 2025 | Isturisa |
| Corcept Therapeutics | $18.54 | 2024 | Korlym |
| Beta Bionics, INC. | $16.99 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.